slide consist of cholinergic system, neuronal transmission, receptors of cholinergic system, anti cholinergic drugs its classification, Mechanism of action and organophosphate poisoning and treatment approaches
This document provides an overview of butyrylcholinesterase (BChE), including its substrates, inhibitors, structure, mechanism of action, and therapeutic indications. It discusses the biochemistry and genetic variability of BChE, as well as its role in protecting against toxicities and disease. BChE preferentially hydrolyzes butyrylcholine and can also hydrolyze acetylcholine and various drugs like cocaine. Inherited BChE deficiencies have implications for responses to drugs like succinylcholine. Enhancing BChE activity may help treat cocaine abuse and toxicity.
This document provides an outline for a lecture on cholinergic antagonists. It will cover muscarinic antagonists, their therapeutic applications and structure-activity relationships. It will also cover nicotinic antagonists, including their use as neuromuscular blockers. The learning objectives are to understand the structures, uses and binding properties of various cholinergic antagonists, and how their chemical structures relate to their activities. Key topics include the pharmacophores of antimuscarinics, specific drugs from different classes, and differences between depolarizing and non-depolarizing neuromuscular blockers.
Anticholinergics are drugs that inhibit the pharmacological response of acetylcholine (Ach) by competitively binding to and blocking muscarinic receptors. Their general structure consists of two carbocyclic or heterocyclic rings (R1 and R2) connected by a chain with an ester or ether group (X) and a basic nitrogen substituent. The R3 group can be hydrogen, hydroxyl, or hydroxymethyl. Maximum potency is seen with 2 carbon units between the ring and nitrogen. Older anticholinergics like atropine and scopolamine are non-selective for muscarinic receptor subtypes, while newer drugs show selectivity. Anticholinergics are used to treat
1. Cholinergic drugs act as agonists at cholinergic receptors and include direct-acting receptor agonists like acetylcholine and indirect-acting cholinesterase inhibitors.
2. Direct-acting agonists can be classified based on their receptor specificity and susceptibility to acetylcholinesterase hydrolysis. Indirect agonists inhibit acetylcholinesterase and butyrylcholinesterase to prolong the action of endogenous acetylcholine.
3. Cholinergic drugs have various effects in the body including contraction of muscles in the eye, increased secretions, changes in heart rate and breathing, and activation of the parasympathetic nervous system. Their effects are mediated through muscar
slide consist of cholinergic system, neuronal transmission, receptors of cholinergic system, anti cholinergic drugs its classification, Mechanism of action and organophosphate poisoning and treatment approaches
This document provides an overview of butyrylcholinesterase (BChE), including its substrates, inhibitors, structure, mechanism of action, and therapeutic indications. It discusses the biochemistry and genetic variability of BChE, as well as its role in protecting against toxicities and disease. BChE preferentially hydrolyzes butyrylcholine and can also hydrolyze acetylcholine and various drugs like cocaine. Inherited BChE deficiencies have implications for responses to drugs like succinylcholine. Enhancing BChE activity may help treat cocaine abuse and toxicity.
This document provides an outline for a lecture on cholinergic antagonists. It will cover muscarinic antagonists, their therapeutic applications and structure-activity relationships. It will also cover nicotinic antagonists, including their use as neuromuscular blockers. The learning objectives are to understand the structures, uses and binding properties of various cholinergic antagonists, and how their chemical structures relate to their activities. Key topics include the pharmacophores of antimuscarinics, specific drugs from different classes, and differences between depolarizing and non-depolarizing neuromuscular blockers.
Anticholinergics are drugs that inhibit the pharmacological response of acetylcholine (Ach) by competitively binding to and blocking muscarinic receptors. Their general structure consists of two carbocyclic or heterocyclic rings (R1 and R2) connected by a chain with an ester or ether group (X) and a basic nitrogen substituent. The R3 group can be hydrogen, hydroxyl, or hydroxymethyl. Maximum potency is seen with 2 carbon units between the ring and nitrogen. Older anticholinergics like atropine and scopolamine are non-selective for muscarinic receptor subtypes, while newer drugs show selectivity. Anticholinergics are used to treat
1. Cholinergic drugs act as agonists at cholinergic receptors and include direct-acting receptor agonists like acetylcholine and indirect-acting cholinesterase inhibitors.
2. Direct-acting agonists can be classified based on their receptor specificity and susceptibility to acetylcholinesterase hydrolysis. Indirect agonists inhibit acetylcholinesterase and butyrylcholinesterase to prolong the action of endogenous acetylcholine.
3. Cholinergic drugs have various effects in the body including contraction of muscles in the eye, increased secretions, changes in heart rate and breathing, and activation of the parasympathetic nervous system. Their effects are mediated through muscar
This document summarizes information about cholinergic transmission and drugs that act on the cholinergic system. It discusses acetylcholine as a neurotransmitter and its roles. It describes the distribution of muscarinic and nicotinic receptors and the effects of cholinergic drugs. Specifically, it covers direct and indirect cholinergic agonists as well as anticholinesterases and antimuscarinic drugs. It also provides information on myasthenia gravis and organophosphate poisoning, including associated signs/symptoms and treatment approaches.
Acetylcholinesterase inhibitors : Dr Rahul KunkulolRahul Kunkulol
This document discusses anticholinesterase drugs and their mechanisms and uses. It describes how anticholinesterases inhibit the enzyme acetylcholinesterase, preventing the breakdown of acetylcholine and thereby increasing cholinergic neurotransmission. The main types discussed are reversible carbamate drugs like physostigmine and neostigmine, and irreversible organophosphate inhibitors. Their uses include treating glaucoma, myasthenia gravis, and as antidotes for organophosphate poisoning. The mechanisms and characteristics of specific drugs like physostigmine, neostigmine, and edrophonium are also compared.
Introduction to Opioid analgesis, Terms, History, Classification, Morphine, Opioid receptors, Mechanism of action, Pharmacological actions of morphine, Pharmacokinetics, Adverse effects, Contraindications, Therapeutic uses
Presented by
B . Kranthi Kumar
Department of Pharmacology
This presentation deals with the various cholinergic (acetylcholine) and anti-cholinergic drugs (atropine) alongwith a brief description of the various muscarinic receptors and nicotinic receptors. Also, it includes various agonists & antagonists with a brief description of organophosphorous poisoning at the end.
1. The document discusses the history, pharmacological properties, advantages, and unfavorable conditions of sevoflurane.
2. It provides details on the development of sevoflurane from the 1960s onward and its approval for use in humans in the 1990s.
3. The document also examines sevoflurane's effects on various body systems and compares it to other inhalational anesthetics like isoflurane, noting sevoflurane's favorable properties like rapid induction/recovery and brain protective effects.
Pharmacology of Cholinergic Drugs. It contains a detailed elaboration of Cholinergic Agents, Cholinomimmetics, Cholinergic Antagonists, Synthesis of Ach, Receptors, Classification, Mechanism of Action, Pharmacokinetics and Dynamics, Dosage and Adverse effects
This document summarizes cholinergic antagonists, which are drugs that block the effects of acetylcholine in the muscarinic receptor. It discusses their structure-activity relationships, medical uses in conditions like ulcers, overactive bladder, and organophosphate poisoning. Specific antagonists are described like atropine, hyoscyamine, scopolamine, ipratropium, tiotropium, benztropine, biperiden, tropicamide, and others. Their mechanisms of action, pharmacological effects, and clinical applications are concisely outlined.
The document discusses cholinergic blockers, also known as cholinolytics, which are drugs that reduce the effects of acetylcholine by blocking muscarinic and nicotinic receptors. It covers the mechanism of action, classification, and examples of important cholinergic blockers like atropine, hyoscine, and ipratropium. The summary also mentions side effects of cholinergic blockers and provides syntheses of selected compounds like ipratropium bromide and dicyclomine.
Propofol, thiopentone, ketamine, dexmedetomidine, and etomidate are common induction agents used in anesthesia. Propofol acts through GABA receptors and has a rapid onset and short duration. Thiopentone is a barbiturate that also acts through GABA, has a very rapid onset due to high lipid solubility, and a longer duration. Ketamine is a dissociative anesthetic that acts through NMDA receptors and has analgesic properties with a rapid onset but longer duration than other agents. Dexmedetomidine is a sedative that acts through alpha-2 receptors. Etomidate is a nonbarbiturate hypnotic that acts through modulation
1. Organophosphate and carbamate insecticides interfere with the breakdown of the neurotransmitter acetylcholine, resulting in overstimulation of nerves and muscles. They do this by inhibiting the enzyme acetylcholinesterase, preventing the breakdown of acetylcholine at nerve junctions.
2. Clinical signs include excessive salivation, vomiting, urination, defecation, muscle tremors, weakness and paralysis as a result of continuous stimulation of nerves and fatigue of muscles. Respiratory symptoms can also occur.
3. Treatment involves managing the airway, providing oxygen and intravenous fluids, controlling seizures and muscle activity, removing any unabsorbed insecticide from the stomach, using atropine to reduce mus
This document discusses perioperative anaphylaxis, including its epidemiology, pathophysiology, causes, clinical features, management, reporting and follow up, and future considerations for anaesthesia. Perioperative anaphylaxis has an incidence of 1 in 10,000-11,752 cases and a mortality rate of 0-4%. It is usually IgE-mediated and occurs within minutes of induction. Common causes include antibiotics, neuromuscular blockers, colloids, and induction agents. Management involves stopping causative agents, epinephrine, fluids, antihistamines, corticosteroids, and bronchodilators as needed. Tests include histamine, tryptase, skin testing, and
Basics of anatomy of endocrine glands and functions of their hormones with disorders as per the Pharmacy Council of India curriculum.
Only for educational purpose for undergraduate B pharmacy students.
This document summarizes methods for screening sympathomimetic and sympatholytic drugs. Sympathomimetics mimic epinephrine and stimulate the sympathetic nervous system, while sympatholytics block these effects. Screening methods include in vivo tests using cat spleens or measuring nictitating membrane prolapse in cats. In vitro tests involve measuring contractions of rabbit pulmonary arteries, rat vas deferens, or cat spleen strips in response to drugs. These assays allow evaluating sympatholytic potency by assessing the ability of test drugs to reduce contractions caused by agonists like epinephrine and norepinephrine.
This document discusses various in vitro and in vivo models for screening antipsychotic drugs. It begins by providing background on schizophrenia and antipsychotic drugs. It then describes two important in vitro models - the D1 receptor assay using 3H-SCH 23390 binding and the D2 receptor assay using 3H spiroperidol binding. Both assays are used to determine binding affinity of test compounds to dopamine receptors. Three key in vivo models are also outlined - the open field test to evaluate motor activity, the rota rod test to assess motor coordination, and the grip strength test to measure muscular strength. The document provides details on the procedures and evaluation of these screening models.
Antimuscarinic agents act by blocking cholinergic receptors, specifically muscarinic receptors. They can block muscarinic receptors non-selectively or selectively at M1, M2, or M3 receptors. Atropine and scopolamine are examples of non-selective muscarinic antagonists. These agents have various therapeutic effects including pupil dilation, reduced secretions, and bronchodilation due to their antimuscarinic properties. They are used for conditions like mydriasis, secretions in respiratory diseases, and bradycardia. Common side effects include dry mouth, blurred vision, constipation, difficulty urinating, and tachycardia.
This document provides information about atropine and glycopyrrolate, including their structure, mechanisms of action, pharmacokinetics, clinical uses, and comparisons. Atropine is a competitive muscarinic receptor antagonist derived from plants. It has central nervous system and cardiovascular effects. Glycopyrrolate is a quaternary ammonium anticholinergic that does not cross the blood brain barrier, so it has fewer central effects. Both drugs are used preoperatively and to reverse neuromuscular blockade. Glycopyrrolate is preferred to atropine for premedication due to its more stable hemodynamic profile and lack of cognitive effects.
1) Dextromethorphan, a drug that inhibits serotonin reuptake, blocks the acute depletion of brain serotonin caused by p-chloroamphetamine (PCA) and H75/12 in rats.
2) Dextromethorphan's ability to inhibit the serotonin transporter likely explains how it prevents both the short-term reversible depletion and long-term neurotoxic depletion caused by PCA.
3) The findings suggest dextromethorphan inhibits the serotonin transporter in vivo, as evidenced by its decreasing brain levels of 5-HIAA while not affecting serotonin levels. This mechanism, not an effect on calcium channels, best explains dextromethorphan's protective effects against PCA
Introduction
parasympathetic nervous system
cholinergic drugs
Anticholinergic agents
Divisions of Autonomous nervous system
Drugs acting on adrenergic nervous system
Adrenergic agents
This document provides an overview of anticholinergic drugs, including:
- Their classification into natural alkaloids, semisynthetic derivatives, and synthetic compounds.
- Their mechanisms of action as muscarinic receptor antagonists and effects on various organ systems like the CNS, eyes, cardiovascular, respiratory, gastrointestinal, and urinary systems.
- Examples of individual drugs from each class and their therapeutic uses for conditions like Parkinson's disease, peptic ulcers, overactive bladder, respiratory diseases, and more.
- Information on pharmacokinetics, pharmacology, interactions, contraindications, and belladonna poisoning from anticholinergic overdose.
This is an lecture presentation for MBBS Semester 1 students. Here we discuss cholinergic agonists and anticholinesterase drugs. We end up discussing about OP poisoning in brief.
This document provides information about the parasympathetic nervous system and cholinergic agents. It begins by outlining learning objectives about defining the biochemistry of the parasympathetic system, classifying agonists and antagonists, and explaining the structure-activity relationship of acetylcholine. It then discusses the anatomy and functions of the motor nerves, including the roles of acetylcholine. The document outlines the SAR of acetylcholine and binding interactions. It describes cholinergic agonists and antagonists, including clinical uses. Muscarinic and nicotinic receptors and their subtypes are defined. The actions and uses of cholinergic drugs like atropine and tubocurarine are summarized.
Part II: UNIT cholinergic neurotransmitter - Antagonist DrugsSONALI PAWAR
This document discusses cholinergic neurotransmitters and cholinergic blocking agents. It begins by describing various cholinergic blocking agents including solanaceous alkaloids like atropine, scopolamine, and hyoscyamine as well as synthetic agents like tropicamide, cyclopentolate, dicyclomine, glycopyrrolate, and propantheline. It then discusses the mechanisms of action and medical uses of these drugs, which work by antagonizing acetylcholine at nicotinic or muscarinic receptors. The document also covers structural activity relationships of parasympatholytic agents and their use in treating conditions like smooth muscle spasms, ulcers, overactive bladder, and Parkinson
This document summarizes information about cholinergic transmission and drugs that act on the cholinergic system. It discusses acetylcholine as a neurotransmitter and its roles. It describes the distribution of muscarinic and nicotinic receptors and the effects of cholinergic drugs. Specifically, it covers direct and indirect cholinergic agonists as well as anticholinesterases and antimuscarinic drugs. It also provides information on myasthenia gravis and organophosphate poisoning, including associated signs/symptoms and treatment approaches.
Acetylcholinesterase inhibitors : Dr Rahul KunkulolRahul Kunkulol
This document discusses anticholinesterase drugs and their mechanisms and uses. It describes how anticholinesterases inhibit the enzyme acetylcholinesterase, preventing the breakdown of acetylcholine and thereby increasing cholinergic neurotransmission. The main types discussed are reversible carbamate drugs like physostigmine and neostigmine, and irreversible organophosphate inhibitors. Their uses include treating glaucoma, myasthenia gravis, and as antidotes for organophosphate poisoning. The mechanisms and characteristics of specific drugs like physostigmine, neostigmine, and edrophonium are also compared.
Introduction to Opioid analgesis, Terms, History, Classification, Morphine, Opioid receptors, Mechanism of action, Pharmacological actions of morphine, Pharmacokinetics, Adverse effects, Contraindications, Therapeutic uses
Presented by
B . Kranthi Kumar
Department of Pharmacology
This presentation deals with the various cholinergic (acetylcholine) and anti-cholinergic drugs (atropine) alongwith a brief description of the various muscarinic receptors and nicotinic receptors. Also, it includes various agonists & antagonists with a brief description of organophosphorous poisoning at the end.
1. The document discusses the history, pharmacological properties, advantages, and unfavorable conditions of sevoflurane.
2. It provides details on the development of sevoflurane from the 1960s onward and its approval for use in humans in the 1990s.
3. The document also examines sevoflurane's effects on various body systems and compares it to other inhalational anesthetics like isoflurane, noting sevoflurane's favorable properties like rapid induction/recovery and brain protective effects.
Pharmacology of Cholinergic Drugs. It contains a detailed elaboration of Cholinergic Agents, Cholinomimmetics, Cholinergic Antagonists, Synthesis of Ach, Receptors, Classification, Mechanism of Action, Pharmacokinetics and Dynamics, Dosage and Adverse effects
This document summarizes cholinergic antagonists, which are drugs that block the effects of acetylcholine in the muscarinic receptor. It discusses their structure-activity relationships, medical uses in conditions like ulcers, overactive bladder, and organophosphate poisoning. Specific antagonists are described like atropine, hyoscyamine, scopolamine, ipratropium, tiotropium, benztropine, biperiden, tropicamide, and others. Their mechanisms of action, pharmacological effects, and clinical applications are concisely outlined.
The document discusses cholinergic blockers, also known as cholinolytics, which are drugs that reduce the effects of acetylcholine by blocking muscarinic and nicotinic receptors. It covers the mechanism of action, classification, and examples of important cholinergic blockers like atropine, hyoscine, and ipratropium. The summary also mentions side effects of cholinergic blockers and provides syntheses of selected compounds like ipratropium bromide and dicyclomine.
Propofol, thiopentone, ketamine, dexmedetomidine, and etomidate are common induction agents used in anesthesia. Propofol acts through GABA receptors and has a rapid onset and short duration. Thiopentone is a barbiturate that also acts through GABA, has a very rapid onset due to high lipid solubility, and a longer duration. Ketamine is a dissociative anesthetic that acts through NMDA receptors and has analgesic properties with a rapid onset but longer duration than other agents. Dexmedetomidine is a sedative that acts through alpha-2 receptors. Etomidate is a nonbarbiturate hypnotic that acts through modulation
1. Organophosphate and carbamate insecticides interfere with the breakdown of the neurotransmitter acetylcholine, resulting in overstimulation of nerves and muscles. They do this by inhibiting the enzyme acetylcholinesterase, preventing the breakdown of acetylcholine at nerve junctions.
2. Clinical signs include excessive salivation, vomiting, urination, defecation, muscle tremors, weakness and paralysis as a result of continuous stimulation of nerves and fatigue of muscles. Respiratory symptoms can also occur.
3. Treatment involves managing the airway, providing oxygen and intravenous fluids, controlling seizures and muscle activity, removing any unabsorbed insecticide from the stomach, using atropine to reduce mus
This document discusses perioperative anaphylaxis, including its epidemiology, pathophysiology, causes, clinical features, management, reporting and follow up, and future considerations for anaesthesia. Perioperative anaphylaxis has an incidence of 1 in 10,000-11,752 cases and a mortality rate of 0-4%. It is usually IgE-mediated and occurs within minutes of induction. Common causes include antibiotics, neuromuscular blockers, colloids, and induction agents. Management involves stopping causative agents, epinephrine, fluids, antihistamines, corticosteroids, and bronchodilators as needed. Tests include histamine, tryptase, skin testing, and
Basics of anatomy of endocrine glands and functions of their hormones with disorders as per the Pharmacy Council of India curriculum.
Only for educational purpose for undergraduate B pharmacy students.
This document summarizes methods for screening sympathomimetic and sympatholytic drugs. Sympathomimetics mimic epinephrine and stimulate the sympathetic nervous system, while sympatholytics block these effects. Screening methods include in vivo tests using cat spleens or measuring nictitating membrane prolapse in cats. In vitro tests involve measuring contractions of rabbit pulmonary arteries, rat vas deferens, or cat spleen strips in response to drugs. These assays allow evaluating sympatholytic potency by assessing the ability of test drugs to reduce contractions caused by agonists like epinephrine and norepinephrine.
This document discusses various in vitro and in vivo models for screening antipsychotic drugs. It begins by providing background on schizophrenia and antipsychotic drugs. It then describes two important in vitro models - the D1 receptor assay using 3H-SCH 23390 binding and the D2 receptor assay using 3H spiroperidol binding. Both assays are used to determine binding affinity of test compounds to dopamine receptors. Three key in vivo models are also outlined - the open field test to evaluate motor activity, the rota rod test to assess motor coordination, and the grip strength test to measure muscular strength. The document provides details on the procedures and evaluation of these screening models.
Antimuscarinic agents act by blocking cholinergic receptors, specifically muscarinic receptors. They can block muscarinic receptors non-selectively or selectively at M1, M2, or M3 receptors. Atropine and scopolamine are examples of non-selective muscarinic antagonists. These agents have various therapeutic effects including pupil dilation, reduced secretions, and bronchodilation due to their antimuscarinic properties. They are used for conditions like mydriasis, secretions in respiratory diseases, and bradycardia. Common side effects include dry mouth, blurred vision, constipation, difficulty urinating, and tachycardia.
This document provides information about atropine and glycopyrrolate, including their structure, mechanisms of action, pharmacokinetics, clinical uses, and comparisons. Atropine is a competitive muscarinic receptor antagonist derived from plants. It has central nervous system and cardiovascular effects. Glycopyrrolate is a quaternary ammonium anticholinergic that does not cross the blood brain barrier, so it has fewer central effects. Both drugs are used preoperatively and to reverse neuromuscular blockade. Glycopyrrolate is preferred to atropine for premedication due to its more stable hemodynamic profile and lack of cognitive effects.
1) Dextromethorphan, a drug that inhibits serotonin reuptake, blocks the acute depletion of brain serotonin caused by p-chloroamphetamine (PCA) and H75/12 in rats.
2) Dextromethorphan's ability to inhibit the serotonin transporter likely explains how it prevents both the short-term reversible depletion and long-term neurotoxic depletion caused by PCA.
3) The findings suggest dextromethorphan inhibits the serotonin transporter in vivo, as evidenced by its decreasing brain levels of 5-HIAA while not affecting serotonin levels. This mechanism, not an effect on calcium channels, best explains dextromethorphan's protective effects against PCA
Introduction
parasympathetic nervous system
cholinergic drugs
Anticholinergic agents
Divisions of Autonomous nervous system
Drugs acting on adrenergic nervous system
Adrenergic agents
This document provides an overview of anticholinergic drugs, including:
- Their classification into natural alkaloids, semisynthetic derivatives, and synthetic compounds.
- Their mechanisms of action as muscarinic receptor antagonists and effects on various organ systems like the CNS, eyes, cardiovascular, respiratory, gastrointestinal, and urinary systems.
- Examples of individual drugs from each class and their therapeutic uses for conditions like Parkinson's disease, peptic ulcers, overactive bladder, respiratory diseases, and more.
- Information on pharmacokinetics, pharmacology, interactions, contraindications, and belladonna poisoning from anticholinergic overdose.
This is an lecture presentation for MBBS Semester 1 students. Here we discuss cholinergic agonists and anticholinesterase drugs. We end up discussing about OP poisoning in brief.
This document provides information about the parasympathetic nervous system and cholinergic agents. It begins by outlining learning objectives about defining the biochemistry of the parasympathetic system, classifying agonists and antagonists, and explaining the structure-activity relationship of acetylcholine. It then discusses the anatomy and functions of the motor nerves, including the roles of acetylcholine. The document outlines the SAR of acetylcholine and binding interactions. It describes cholinergic agonists and antagonists, including clinical uses. Muscarinic and nicotinic receptors and their subtypes are defined. The actions and uses of cholinergic drugs like atropine and tubocurarine are summarized.
Part II: UNIT cholinergic neurotransmitter - Antagonist DrugsSONALI PAWAR
This document discusses cholinergic neurotransmitters and cholinergic blocking agents. It begins by describing various cholinergic blocking agents including solanaceous alkaloids like atropine, scopolamine, and hyoscyamine as well as synthetic agents like tropicamide, cyclopentolate, dicyclomine, glycopyrrolate, and propantheline. It then discusses the mechanisms of action and medical uses of these drugs, which work by antagonizing acetylcholine at nicotinic or muscarinic receptors. The document also covers structural activity relationships of parasympatholytic agents and their use in treating conditions like smooth muscle spasms, ulcers, overactive bladder, and Parkinson
2 Pharmacology I, intro ANS cholinergic drugs.pptxAhmad Kharousheh
The document provides an overview of the autonomic nervous system, describing the two divisions of the sympathetic and parasympathetic nervous systems. It explains the neurotransmitters involved, including acetylcholine and norepinephrine, and the receptors they act on. The document also discusses the classes of drugs that act on the autonomic nervous system, including direct-acting cholinergic agonists, indirect-acting cholinergic agonists that inhibit acetylcholinesterase, and antimuscarinic drugs that block muscarinic receptors.
Cholinergic+antagonists+by+pharma+raptorsAniket Kale
The document summarizes antimuscarinic drugs. It discusses their mechanism of action as competitive antagonists that block acetylcholine at muscarinic receptors. It classifies antimuscarinics into quaternary and tertiary amines based on their ability to cross the blood-brain barrier. The therapeutic uses include pupil dilation, treatment of asthma, peptic ulcer, and Parkinson's disease. Four categories of antimuscarinics are outlined - solanaceous alkaloids, amino alcohols, amino alcohol esters, and amino ethers. Examples like atropine and ipratropium bromide are described along with their structures, properties, and uses.
Anticholinergics Kampala international university.pptxYIKIISAAC
This document discusses anticholinergic agents, which are drugs that inhibit the action of acetylcholine at cholinergic receptors in the central and peripheral nervous system. It describes the different types of cholinergic receptors, including muscarinic (M1-M5) and nicotinic (N1, N2) receptors. It provides examples of anticholinergic drugs that act as antagonists at these receptors, such as atropine, scopolamine, ipratropium, and ganglionic blockers. The document also discusses the clinical uses of anticholinergic agents for conditions like bradycardia, gastrointestinal disorders, and as pre-operative medications to reduce secretions. The main
Cholinergic blockers and evapouraton factsYashThorat20
The document discusses various cholinergic blocking agents (anticholinergic drugs), including their classification, structures, mechanisms of action, and uses. It begins by listing natural alkaloids found in plants like atropine, hyoscyamine, and scopolamine. It then describes various classes of synthetic anticholinergic drugs like amino alcohol esters, amino ethers, amino alcohols, and amino amides. The document discusses the pharmacological actions and clinical uses of these drugs and provides details on specific examples like ipratropium bromide for bronchodilation in asthma. It also summarizes structure-activity relationships and key features that make drugs more potent muscarinic receptor antagonists.
This document discusses muscarinic acetylcholine receptors and their antagonists. It begins by classifying cholinergic receptors into muscarinic and nicotinic receptors. It then describes the 5 subtypes of muscarinic receptors, their distribution, and examples of agonists and antagonists. A large portion of the document focuses on atropine, describing its pharmacological actions, therapeutic uses, dosing, and adverse effects. Other antimuscarinic drugs discussed include ipratropium, tolterodine, and pirenzepine. The document provides an in-depth overview of muscarinic receptors and antimuscarinic drugs.
Muscarinic receptors bind to acetylcholine and have 5 subtypes that are found in various tissues. Antimuscarinic drugs block these receptors' activity. There are over a dozen antimuscarinic drugs that are used for various conditions by blocking effects of acetylcholine in the CNS, eyes, lungs, gut, and bladder. They work by competitively binding muscarinic receptors. Toxic effects include dry mouth, constipation, blurred vision, urinary retention, fever, and in overdose, delirium, arrhythmias, and seizures. The drugs must be used cautiously in infants, the elderly, and those with glaucoma or prostate issues.
Cholinergic antagonists and blockers-Dr.Jibachha Sah,M.V.Sc,LecturerDr. Jibachha Sah
Dr. Jibachha Sah,M.V.Sc( Veterinary pharmacology, TU,Nepal),posted lecturer notes on AUTONOMIC AND SYSTEMIC PHARMACOLOGY for B.V.Sc & A.H. 6 th semester veterinary students of College of veterinary science,Nepal Polytechnique Institute, Bharatpur, Bhojard, Chitwan, Nepal.I hope this lecture notes may be beneficial for other Nepalese veterinary students. Please send your comment and suggestion .Email:jibachhashah@gmail.com,moble,00977-9845024121
Parasympathomimetic Agents Direct Acting with SAR & Cholinesters Reactivation TejasSuruse
This document discusses parasympathomimetic agents, which are medications that activate the parasympathetic nervous system by mimicking or modifying the effects of acetylcholine. These include direct-acting muscarinic receptor agonists and indirect-acting acetylcholinesterase inhibitors. The document discusses the structure-activity relationship of these agents and how their chemical structure affects biological activity. It classifies parasympathomimetic agents and describes several direct-acting agents, including acetylcholine, carbachol, bethanechol, methacholine, and pilocarpine. It also discusses cholinesterase reactivators like pralidoxime that are used to treat organophosphate poisoning.
A good read for undergraduate students in Pharmacy studying at the University of Mumbai. I will highly recommend Essentials of Medical Pharmacology by KD Tripathi. All copyright to the original authors and publishers.
This document discusses the pharmacology of drugs that act on the autonomic nervous system. It covers cholinergic drugs like acetylcholine agonists and cholinesterase inhibitors which have muscarinic and nicotinic effects. It also discusses anticholinergic drugs that block muscarinic receptors. Additionally, it outlines adrenergic drugs including alpha and beta agonists and antagonists, and their mechanisms and therapeutic uses and side effects. The document provides a detailed overview of pharmacology of the autonomic nervous system.
- Anticholinergic drugs block muscarinic acetylcholine receptors. They include natural alkaloids like atropine and hyoscine, semisynthetic derivatives, and synthetic compounds.
- They are classified based on their use for smooth muscle spasm, nasal congestion, ulcers, overactive bladder, motion sickness, organophosphate poisoning, and Parkinson's disease.
- Structure-activity relationships show anticholinergics have rings connected to a nitrogen, with distance between ring and nitrogen and substituents affecting potency. They may block muscarinic receptors competitively.
cholinergics and anticholinergics presentation.pptxNoorSalam17
Cholinergics and anti cholinergics drugs, definition, indications and contraindications, complications, drugs brand name ,generic name , nursing consideration
Preclinical toxicology studies are conducted in vitro and in vivo in animals to demonstrate a compound's safety before human studies. However, toxicity cannot be fully predicted and compounds still fail in clinical trials for various reasons including mechanism-based pharmacology, reactive metabolites, interactions with other receptors or substances, and idiosyncratic toxicity. Careful consideration of a compound's structure is important to avoid potential toxicity issues like reactive functional groups that could form toxic metabolites or unintended interactions with proteins like the hERG potassium channel. Drug-drug interactions are also a concern if one drug inhibits the metabolic enzymes of another.
Preclinical toxicology studies are conducted in vitro and in vivo in animals to demonstrate a compound's safety before human studies. However, toxicity cannot be fully predicted and compounds still fail in clinical trials for various reasons including mechanism-based pharmacology, reactive metabolites, interactions with other receptors or substances, and idiosyncratic toxicity. Careful consideration of a compound's structure is important to avoid potential toxicity issues like reactive functional groups that could form toxic metabolites or unintended interactions with proteins like the hERG potassium channel. Drug-drug interactions are also a concern if one drug inhibits the metabolic enzymes of another.
Preclinical toxicology studies are conducted in vitro and in vivo in animals to demonstrate a compound's safety before human studies. However, toxic effects are still sometimes observed in human clinical trials despite animal studies. Reasons for failure include mechanism-based pharmacology, reactive metabolites, interactions with other receptors or substances, and idiosyncratic toxicity. Careful consideration of a compound's potential to form reactive metabolites, interact with targets like hERG potassium channels, or inhibit cytochrome P450 enzymes can help predict and avoid toxicities during drug development.
This document summarizes the actions and clinical applications of major adrenergic drugs, including:
1) Sympathomimetics like amphetamine and ephedrine act indirectly by releasing catecholamines from neurons, while direct-acting drugs interact directly with adrenoceptors.
2) Sympatholytics include direct-acting antagonists that block adrenoceptors and indirect-acting drugs that interfere with norepinephrine release or synthesis.
3) Adrenergic drugs have applications for conditions like hypotension, shock, asthma, and hypertension. Common side effects include hypotension, tachycardia, and sedation.
The document discusses parasympathomimetic drugs, which mimic the action of acetylcholine in the parasympathetic nervous system. It describes how acetylcholine is synthesized, stored, and released as a neurotransmitter. It then discusses the two main types of acetylcholine receptors - muscarinic and nicotinic receptors. Parasympathomimetic drugs are classified as either direct-acting agonists that bind acetylcholine receptors or indirect-acting inhibitors of the acetylcholinesterase enzyme. Examples of different classes of parasympathomimetic drugs are provided along with their properties, mechanisms of action, and clinical uses.
Similar to Drugs acting on parasympathetic nervous system2 (20)
The document contains the exam schedule for various pharmacy subjects for B. Pharm students following the 2015, 2018 and 2019 credit patterns. It lists the course name, subject code, subject name, academic year, semester, exam date and time slot for each subject. There are a total of 96 subjects listed with their respective exams scheduled between April 10 to April 27, 2021.
The document discusses the benefits of exercise for mental health. Regular physical activity can help reduce anxiety and depression and improve mood and cognitive function. Exercise causes chemical changes in the brain that may help protect against mental illness and improve symptoms.
Democracy, Election and Governance Syllabus_03.072020.pdfSomu Chaudhari
This document outlines the objectives and modules of a 2-credit compulsory course on democracy, elections, and governance for first-year students of all faculties at Savitribai Phule Pune University. The course aims to introduce students to the meaning of democracy and the role of governance. It will help students understand different approaches to studying democracy and governance. The modules will cover the foundations and dimensions of democracy in India, decentralization, and concepts of governance. References for further reading are provided.
The document announces a mock test for candidates who were not covered in earlier tests, to be held from 19th February 2022 to 20th February 2022. It lists the various degree programs including BA, BBA, BCom, LLB, BHMCT, MBA, MCA, BSc in subjects like Biotech, Hospitality Studies, Computer Science, Animation, and BCA that will be covered in the mock test. The mock test aims to provide an online experience of answering Multiple Choice Questions to help candidates prepare for upcoming online exams.
This document provides the schedule for practical, oral, term work, seminar, mini-project, project, and dissertation examinations for engineering, pharmacy, and architecture programs from May 5th to May 30th 2022. It instructs principals of affiliated colleges to conduct the examinations at the college level by appointing internal and external examiners and submit marks through the internal marks web portal by June 15th 2022. Appropriate health measures must also be taken during the examinations.
PCI syllabus for F. Y. B.Pharm orientationSomu Chaudhari
The document outlines the rules and syllabus for the first year B.Pharm course according to the Pharmacy Council of India. It discusses the minimum qualifications for admission, program structure and credit requirements, coursework and assessments over eight semesters. Key points include following the PCI revised regulations, requiring a 10+2 pass with Physics, Chemistry and Maths/Biology, a minimum of 208 credits to graduate including theory, practical and extracurricular courses, internal assessments, projects, and industrial training. A CGPA system is used to determine class awards and ranks.
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptxHolistified Wellness
We’re talking about Vedic Meditation, a form of meditation that has been around for at least 5,000 years. Back then, the people who lived in the Indus Valley, now known as India and Pakistan, practised meditation as a fundamental part of daily life. This knowledge that has given us yoga and Ayurveda, was known as Veda, hence the name Vedic. And though there are some written records, the practice has been passed down verbally from generation to generation.
Does Over-Masturbation Contribute to Chronic Prostatitis.pptxwalterHu5
In some case, your chronic prostatitis may be related to over-masturbation. Generally, natural medicine Diuretic and Anti-inflammatory Pill can help mee get a cure.
- Video recording of this lecture in English language: https://youtu.be/kqbnxVAZs-0
- Video recording of this lecture in Arabic language: https://youtu.be/SINlygW1Mpc
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
TEST BANK For Basic and Clinical Pharmacology, 14th Edition by Bertram G. Kat...rightmanforbloodline
TEST BANK For Basic and Clinical Pharmacology, 14th Edition by Bertram G. Katzung, Verified Chapters 1 - 66, Complete Newest Version.
TEST BANK For Basic and Clinical Pharmacology, 14th Edition by Bertram G. Katzung, Verified Chapters 1 - 66, Complete Newest Version.
TEST BANK For Basic and Clinical Pharmacology, 14th Edition by Bertram G. Katzung, Verified Chapters 1 - 66, Complete Newest Version.
TEST BANK For Basic and Clinical Pharmacology, 14th Edition by Bertram G. Katzung, Verified Chapters 1 - 66, Complete Newest Version.
Adhd Medication Shortage Uk - trinexpharmacy.comreignlana06
The UK is currently facing a Adhd Medication Shortage Uk, which has left many patients and their families grappling with uncertainty and frustration. ADHD, or Attention Deficit Hyperactivity Disorder, is a chronic condition that requires consistent medication to manage effectively. This shortage has highlighted the critical role these medications play in the daily lives of those affected by ADHD. Contact : +1 (747) 209 – 3649 E-mail : sales@trinexpharmacy.com
TEST BANK For An Introduction to Brain and Behavior, 7th Edition by Bryan Kol...rightmanforbloodline
TEST BANK For An Introduction to Brain and Behavior, 7th Edition by Bryan Kolb, Ian Q. Whishaw, Verified Chapters 1 - 16, Complete Newest Versio
TEST BANK For An Introduction to Brain and Behavior, 7th Edition by Bryan Kolb, Ian Q. Whishaw, Verified Chapters 1 - 16, Complete Newest Version
TEST BANK For An Introduction to Brain and Behavior, 7th Edition by Bryan Kolb, Ian Q. Whishaw, Verified Chapters 1 - 16, Complete Newest Version
share - Lions, tigers, AI and health misinformation, oh my!.pptxTina Purnat
• Pitfalls and pivots needed to use AI effectively in public health
• Evidence-based strategies to address health misinformation effectively
• Building trust with communities online and offline
• Equipping health professionals to address questions, concerns and health misinformation
• Assessing risk and mitigating harm from adverse health narratives in communities, health workforce and health system
Basavarajeeyam is a Sreshta Sangraha grantha (Compiled book ), written by Neelkanta kotturu Basavaraja Virachita. It contains 25 Prakaranas, First 24 Chapters related to Rogas& 25th to Rasadravyas.
Cell Therapy Expansion and Challenges in Autoimmune DiseaseHealth Advances
There is increasing confidence that cell therapies will soon play a role in the treatment of autoimmune disorders, but the extent of this impact remains to be seen. Early readouts on autologous CAR-Ts in lupus are encouraging, but manufacturing and cost limitations are likely to restrict access to highly refractory patients. Allogeneic CAR-Ts have the potential to broaden access to earlier lines of treatment due to their inherent cost benefits, however they will need to demonstrate comparable or improved efficacy to established modalities.
In addition to infrastructure and capacity constraints, CAR-Ts face a very different risk-benefit dynamic in autoimmune compared to oncology, highlighting the need for tolerable therapies with low adverse event risk. CAR-NK and Treg-based therapies are also being developed in certain autoimmune disorders and may demonstrate favorable safety profiles. Several novel non-cell therapies such as bispecific antibodies, nanobodies, and RNAi drugs, may also offer future alternative competitive solutions with variable value propositions.
Widespread adoption of cell therapies will not only require strong efficacy and safety data, but also adapted pricing and access strategies. At oncology-based price points, CAR-Ts are unlikely to achieve broad market access in autoimmune disorders, with eligible patient populations that are potentially orders of magnitude greater than the number of currently addressable cancer patients. Developers have made strides towards reducing cell therapy COGS while improving manufacturing efficiency, but payors will inevitably restrict access until more sustainable pricing is achieved.
Despite these headwinds, industry leaders and investors remain confident that cell therapies are poised to address significant unmet need in patients suffering from autoimmune disorders. However, the extent of this impact on the treatment landscape remains to be seen, as the industry rapidly approaches an inflection point.
Cell Therapy Expansion and Challenges in Autoimmune Disease
Drugs acting on parasympathetic nervous system2
1. CHOLINERGICS, ANTICHOLINERGICS
& ANTICHOLINESTERASES
Part 2: Cholinergics & anticholinesterases
Mr. Somdatta Y Chaudhari
Dept. of Pharm. Chemistry
P.E.S. Modern College of Pharmacy, Nigdi
P.E.S. Modern College of Pharmacy, Nigdi 1
2. Contents
Part 2: Cholinergics & anticholinesterases
12. Cholinergic Antagonists (Muscarinic receptor) (2 slides)
12.1. Atropine
12.2. Hyoscine (scopolamine)
12.3. Comparison of atropine with acetylcholine
12.4. Analogues of atropine
12.5. Simplified Analogues (2 slides)
12.6. SAR for Antagonists (3 slides)
12.7. Binding Site for Antagonists (2 slides)
13. Cholinergic Antagonists (Nicotinic receptor)
13.1. Curare (2 slides)
13.2. Binding
13.3. Analogues of tubocurarine (5 slides)
P.E.S. Modern College of Pharmacy, Nigdi 2
3. 12. Cholinergic Antagonists (Muscarinic receptor)
• Drugs which bind to cholinergic receptor but do not activate it
• Prevent acetylcholine from binding
• Opposite clinical effect to agonists - lower activity of
acetylcholine
Postsynaptic
nerve
Ach
Antagonist
Ach
Postsynaptic
nerve
Ach
P.E.S. Modern College of Pharmacy, Nigdi 3
4. 12. Cholinergic Antagonists (Muscarinic receptor)
Clinical Effects
• Decrease of saliva and gastric secretions
• Relaxation of smooth muscle
• Decrease in motility of GIT and urinary tract
• Dilation of pupils
Uses
• Shutting down digestion for surgery
• Ophthalmic examinations
• Relief of peptic ulcers
• Treatment of Parkinson’s Disease
• Anticholinesterase poisoning
• Motion sickness
P.E.S. Modern College of Pharmacy, Nigdi 4
5. 12.1 Atropine
• Racemic form of hyoscyamine
• Source - roots of belladonna (1831) (deadly nightshade)
• Used as a poison
• Used as a medicine
decreases GIT motility
antidote for anticholinesterase poisoning
dilation of eye pupils
• CNS side effects – hallucinations
*
N
H
O
C
O
Me
CH
CH2OH
easily racemised
12. Cholinergic Antagonists (Muscarinic receptor)
P.E.S. Modern College of Pharmacy, Nigdi 5
6. • Opthalmic use of atropine a as mydriatic (dilating) agent
has been largely replaced by use of analogs tropicamide
and cyclopenatolate (vida infra).
• However, atropine, and its chiral analog hyoscyamine,
are utilized to treat gastrointestinal disorders
• Also these antagonists can be used to treat the symptoms
of an excess of acetylcholine, such as might occur upon
exposure to an inhibitor of the enzyme acetylcholinesterase
(such as a nerve gas).P.E.S. Modern College of Pharmacy, Nigdi 6
7. • Atropine is also used to avoid bradycardia (too slow heart rate) during some
procedures (such as pediatric RSI, rapid sequence intubation), which also use
succinylcholine (suxamethonium chloride) as a neuromuscular blocking agent
(antagonist at the nicotinic Ach receptors).
• As shown in the diagram above, the atropine serves as an antagonist of acetycholine
at the M2 receptor of the sinoatrial node.
• The acetylcholine at this junction triggers a GPCR using the Gi G-protein, normally
leading to decrease in the levels of cAMP. Thus the atropine restores normal levels of
cAMP, reversing the effects of vagus nerve stimulation.
P.E.S. Modern College of Pharmacy, Nigdi 7
8. 12.2 Hyoscine (scopolamine)
• Source - thorn apple
• Medical use - treatment of motion sickness
• Used as a truth drug (CNS effects)
*
N
H
O
C
O
Me
CH
CH2OHO
H
H
12. Cholinergic Antagonists (Muscarinic receptor)
P.E.S. Modern College of Pharmacy, Nigdi 8
10. 12.3 Comparison of atropine with acetylcholine
• Relative positions of ester and nitrogen similar in both molecules
• Nitrogen in atropine is ionised
• Amine and ester are important binding groups (ionic + H-bonds)
• Aromatic ring of atropine is an extra binding group (vdW)
• Atropine binds with a different induced fit - no activation
• Atropine binds more strongly than acetylcholine
N
O
C
O
Me
H
CH
CH2OH
C
O
O CH3
NMe3
CH2CH2
12. Cholinergic Antagonists (Muscarinic receptor)
P.E.S. Modern College of Pharmacy, Nigdi 10
11. 12.4 Analogues of atropine
• Analogues are fully ionised
• Analogues unable to cross the blood brain barrier
• No CNS side effects
Atropine methonitrate
(lowers GIT motility)
N
H
O
C
O
CH3
CH
CH2OH
H3C
NO3
Ipratropium
(bronchodilator & anti-asthmatic)
N
H
O
C
O
CH(CH3)2
CH
CH2OH
H3C
Br
12. Cholinergic Antagonists (Muscarinic receptor)
P.E.S. Modern College of Pharmacy, Nigdi 11
12. The combination preparation ipratropium/salbutamol is a formulation containing ipratropium bromide and
salbutamol sulfate (albuterol sulfate) used in the management of chronic obstructive pulmonary disease (COPD)
and asthma. It is marketed by Boehringer Ingelheim as metered dose inhaler (MDI) and nebuliser preparations
under the trade name Combivent.
Medications commonly used in asthma and COPD (primarily R03) edit
Anticholinergics: Ipratropium, Tiotropium
Short acting β2-agonists: Salbutamol, Terbutaline
Long acting β2-agonists (LABA): Bambuterol, Clenbuterol, Fenoterol, Formoterol, Salmeterol
Corticosteroids: Beclometasone, Budesonide, Ciclesonide, Fluticasone
Leukotriene antagonists: Montelukast, Pranlukast, Zafirlukast
Xanthines: Aminophylline, Theobromine, Theophylline
Mast cell stabilizers: Cromoglicate, Nedocromil
Combination products: Budesonide/formoterol, Fluticasone/salmeterol, Ipratropium/salbutamol
P.E.S. Modern College of Pharmacy, Nigdi 12
13. 12.5 Simplified Analogues
Pharmacophore = ester + basic amine + aromatic ring
Amprotropine
N
CH2
CH2
CH2
O
C
O
Et
CH
CH2OH
Et
Tridihexethyl bromide
HO C CH2CH2N(Et)3 Br
Propantheline chloride
Cl
O C
O
O CH2CH2 N
CH
Me
CH
Me Me
Me
Me
12. Cholinergic Antagonists (Muscarinic receptor)
P.E.S. Modern College of Pharmacy, Nigdi 13
15. Tropicamide
Cyclopentolate
• Tropicamide and Cyclopentolate (above) are among the most
commonly employed mydriatic (dilating) and cycloplegic
(paralyzing) agents
• Both function as antagonists at the muscarinic acetylcholine
receptors P.E.S. Modern College of Pharmacy, Nigdi 15
16. 12.6 SAR for Antagonists
Important features
• Tertiary amine (ionised) or a quaternary nitrogen
• Aromatic ring
• Ester
• N-Alkyl groups (R) can be larger than methyl (unlike agonists)
• Large branched acyl group
• R’ = aromatic or heteroaromatic ring
• Branching of aromatic/heteroaromatic rings is important
R2N
CH2
CH2
O
C
O
CH
R'
R'
R' = Aromatic or
Heteroaromatic
12. Cholinergic Antagonists (Muscarinic receptor)
P.E.S. Modern College of Pharmacy, Nigdi 16
17. InactiveActive
Cl
O C
O
O CH2CH2 N
CH
Me
CH
Me Me
Me
Me CH2
C
O
O CH2CH2NR2
12.6 SAR for Antagonists
12. Cholinergic Antagonists (Muscarinic receptor)
P.E.S. Modern College of Pharmacy, Nigdi 17
18. Tertiary amine (ionised)
or quaternary nitrogen
Aromatic ring
Ester
N-Alkyl groups (R) can be
larger than methyl
R’ = aromatic or heteroaromatic
Branching of Ar rings important
Quaternary nitrogen
Aromatic ring
Ester
N-Alkyl groups = methyl
R’ = H
SAR for Antagonists SAR for Agonists
12.6 SAR for Antagonists vs. Agonists
12. Cholinergic Antagonists (Muscarinic receptor)
P.E.S. Modern College of Pharmacy, Nigdi 18
19. RECEPTOR SURFACE
Acetylcholine
binding site
12.7 Binding Site for Antagonists
van der Waals
binding regions
for antagonists
12. Cholinergic Antagonists (Muscarinic receptor)
P.E.S. Modern College of Pharmacy, Nigdi 19
20. 12.7 Binding Site for Antagonists
CH
Me
Me
CH
MeMe
N
Me
CH2CH2O
C
O
O
Cl
H2N Asn
CO2
CH2
CH2
O
O
C
NMeR2
O
12. Cholinergic Antagonists (Muscarinic receptor)
P.E.S. Modern College of Pharmacy, Nigdi 20
21. 13. Cholinergic Antagonists (Nicotinic receptor)
13.1 Curare
• Extract from ourari plant
• Used for poison arrows
• Causes paralysis (blocks acetylcholine signals to muscles)
• Active principle = tubocurarine
Tubocurarine
N
HO
MeO
O
CH2
OMe
N
Me
Me
H
O
Me
CH2
OH
H
H
P.E.S. Modern College of Pharmacy, Nigdi 21
22. Tubocurarine chloride is a competitive antagonist of nicotinic neuromuscular
acetylcholine receptors, It is one of the chemicals that can be obtained from curare,
itself an extract of Chondodendron tomentosum, a plant found in South American
jungles which is used as a source of arrow poison. Native indians hunting animals
with this poison were able to eat the animal's contaminated flesh without being
affected by the toxin because tubocurarine cannot easily cross mucous
membranes and is thus inactive orally.
P.E.S. Modern College of Pharmacy, Nigdi 22
23. • Tubocurarine began to be
clinically utilized as a surgical
neuromuscular blocking agent in
the 1940’s
• This drug has been supplanted
by safer medicines, but is still
utilized as part of the lethal
injection procedure.
P.E.S. Modern College of Pharmacy, Nigdi 23
24. 13. Cholinergic Antagonists (Nicotinic receptor)
Pharmacophore
• Two quaternary centres at specific separation (1.15nm)
• Different mechanism of action from atropine based antagonists
• Different binding interactions
Clinical uses
• Neuromuscular blocker for surgical operations
• Permits lower and safer levels of general anaesthetic
• Tubocurarine used as neuromuscular blocker but side effects
P.E.S. Modern College of Pharmacy, Nigdi 24
25. 13.2 Binding
a) Receptor dimer
S
b) Interaction with tubocurarine
protein complex
(5 subunits)
diameter=8nm
8nm
9-10nm
N N
N N Tubocurarine
Acetylcholine binding site
13. Cholinergic Antagonists (Nicotinic receptor)
P.E.S. Modern College of Pharmacy, Nigdi 25
26. 13.3 Analogues of tubocurarine
• Long lasting
• Long recovery times
• Side effects on heart
• No longer in clinical use
Decamethonium
Me3N(CH2)10NMe3
13. Cholinergic Antagonists (Nicotinic receptor)
P.E.S. Modern College of Pharmacy, Nigdi 26
28. 13.3 Analogues of tubocurarine
• Steroid acts as a spacer for the quaternary centres (1.09nm)
• Acyl groups are added to introduce the Ach skeleton
• Faster onset then tubocurarine but slower than suxamethonium
• Longer duration of action than suxamethonium (45 min)
• No effect on blood pressure and fewer side effects
13. Cholinergic Antagonists (Nicotinic receptor)
Pancuronium (R=Me)
Vecuronium (R=H)
Me
O
NMe
N
O
Me
Me
Me
O
O
H
H H
H
P.E.S. Modern College of Pharmacy, Nigdi 28
29. • Pancuronium is used to block the neuromuscular junction during
surgery or intubation.
• In the US, pancuronium (pavulon) is the second of three drugs used
in execution by lethal injection
• Lawsuits against the lethal injection procedure have charged that
this drug would make the patient unable to cry out if he was in pain, as
might occur if insufficient sodium thiopentol (the anesthetic) had been
administered P.E.S. Modern College of Pharmacy, Nigdi 29
30. 13.3 Analogues of tubocurarine
• Design based on tubocurarine and suxamethonium
• Lacks cardiac side effects
• Rapidly broken down in blood both chemically and metabolically
• Avoids patient variation in metabolic enzymes
• Lifetime is 30 minutes
• Administered as an i.v. drip
• Self destruct system limits lifetime
Atracurium
N
CH2 CH2
C
O
O
MeO
OMe
H
N
(CH2)5MeO O
C
OMe
O
CH2 CH2
Me
MeO
OMe
OMe
OMe
13. Cholinergic Antagonists (Nicotinic receptor)
P.E.S. Modern College of Pharmacy, Nigdi 30
31. 13.3 Analogues of tubocurarine
Atracurium stable at acid pH
Hofmann elimination at blood pH (7.4)
N
Me
CH2
Ph
CH C
H
O
R
ACTIVE
-H
CHH2C C
O
Ph
R
N
Me
INACTIVE
13. Cholinergic Antagonists (Nicotinic receptor)
P.E.S. Modern College of Pharmacy, Nigdi 31
32. • An improved version of atracurium is the purified form of just one of the ten
possible stereoisomers, that has the highest efficacy and least side effects
• The name of the blocking agent is cisatracurium (NIMBEX)
• This is the most widely used agent surgically.
• 80% of the drug is metabolized via Hofmann elimination, thus lowering variability
in patients with possible liver or renal disease.
• The Hofmann degradation is only dependent on the pH and temperature of the
plasma.
P.E.S. Modern College of Pharmacy, Nigdi 32
33. 13.3 Analogues of tubocurarine
Mivacurium
• Faster onset (2 min)
• Shorter duration (15 min)
13. Cholinergic Antagonists (Nicotinic receptor)
N
MeO
OMe
H3C
NMeO
OMe
Me
MeO
OMe
OMe
OMe
O
O
O
O
P.E.S. Modern College of Pharmacy, Nigdi 33
34. • The use of mivacurium has declined in recent years, in
favor of other agents with better overall profile.
P.E.S. Modern College of Pharmacy, Nigdi 34